Picture: Andera Partners

Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.

© Lonza Group Ltd.

Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.

Picture: Charnwood Molecular

Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.

Ecotec is part of the Gram-Negative Antibacterials NOW (GNA NOW) consortium within the Innovative Medicine Initaitive's AMR Accelerator. © AdobeStock

Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR).

Production at Pierre Fabre Médicaments. © Pierre Fabre

French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.

German Regional Court in Düsseldorf. © Justiz NRW

German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.